The new QIAsprint Connect is a next generation system for automated high-throughput nucleic acid purification, bringing together walk-away automation, flexible workflows and sustainable design – built for labs that want more control and less manual handling: High-throughput […]
Opella announces a strategic and exclusive partnership with Verb Biotics for the development of a next-generation probiotic strain and its commercialization. This collaboration merges Opella’s ability to take ideas from concept to execution at global […]
Biology is undergoing a structural shift. For decades, progress was driven primarily by experimentation and observation, with each study generating valuable but often isolated insights. Today, multi-omics technologies, automation, large-scale data integration, and AI are […]
A global atlas mapping two key gut bacteria in infants around the world has uncovered a treasure trove of bacterial strains adapted to the infant gut and not found in commercial probiotic products. It lays […]
Not so long ago the gut microbiome was considered a scientific curiosity. Today it’s impossible to ignore. The trillions of microorganisms living in our gastrointestinal tract influence digestion, immunity, metabolism and even mental health. When […]
Gut health has become a familiar term in both scientific papers and marketing campaigns. Although scientists generally agree that gut health is a key component of overall health and wellness, the concept of gut health […]
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. […]
For decades, gynecological tests have relied on a simplified view of the vaginal microbiome, categorizing bacteria as either “good” or “bad.” New research from University of Maryland School of Medicine scientists challenges that assumption, revealing […]
Verb Biotics U.S. Consumer Health Survey of 2,000 adults reported that 73% of consumers experience symptoms related to mental health, including stress and poor sleep. Among these, 40% said their symptoms affect daily functioning, highlighting […]
EnteroBiotix, a clinical-stage biopharmaceutical company focused on developing best-in-class therapies for gut health, today announced positive final results from TrIuMPH, a Phase 2a clinical trial evaluating EBX-102-02, a next-generation oral full-spectrum microbiome therapeutic, in patients […]
AOB Pharma, Inc. (“AOBiome”), a leading clinical-stage biotechnology company focusing on inflammatory skin conditions with their lead asset B244 for the treatment of mild to moderate atopic dermatitis (AD) and pruritus, received a positive decision […]